Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies. Also include pharmaceutical retailers and companies which provide health information services. Companies in this sector include AstraZeneca, Pfizer, and Roche Holding, Walgreens Boots Alliance, and Cerner Corp.
Market Cap
8.829T
Market Weight
9.97%
Industries
11
Companies
1128
Healthcare
S&P 500 ^GSPC
Loading chart for Healthcare
Day Return
Sector
2.15%
S&P 500
0.30%
YTD Return
Sector
22.01%
S&P 500
11.95%
1-Year Return
Sector
31.28%
S&P 500
12.04%
3-Year Return
Sector
57.74%
S&P 500
87.51%
5-Year Return
Sector
30.41%
S&P 500
67.64%
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
Industry
Market Weight
YTD Return
All Industries
22.01%
Drug Manufacturers - General
39.99%
Biotechnology
21.48%
Diagnostics & Research
23.99%
Medical Devices
-8.95%
Healthcare Plans
22.26%
Medical Instruments & Supplies
-5.96%
Medical Distribution
8.68%
Drug Manufacturers - Specialty & Generic
27.38%
Medical Care Facilities
11.03%
Health Information Services
-7.34%
Pharmaceutical Retailers
-34.56%
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
Day Return
--
Market Weight
--
YTD Return
--
Drug Manufacturers - General
+3.63%
Biotechnology
+0.32%
Diagnostics & Research
+0.76%
Medical Devices
+2.10%
Healthcare Plans
+0.56%
Medical Instruments & Supplies
+0.95%
Medical Distribution
+1.77%
Drug Manufacturers - Specialty & Generic
+2.02%
Medical Care Facilities
+2.72%
Health Information Services
+0.07%
<= -3
-2.4
-1.8
-1.2
-0.6
0
0.6
1.2
1.8
2.4
>= 3
Largest Companies in This Sector
View More| Name
|
Last Price
|
1Y Target Est.
|
Market Weight
|
Market Cap
|
Day Change %
|
YTD Return
|
Avg. Analyst Rating
|
|---|---|---|---|---|---|---|---|
| 1,373.00 | 1,333.72 | 14.54% | 1.224T | +6.57% | +27.76% | Buy
|
|
| 275.20 | 279.41 | 7.87% | 662.492B | +1.53% | +32.98% | Buy
|
|
| 290.79 | 283.19 | 6.10% | 513.86B | +1.68% | +27.27% | Buy
|
|
| 410.91 | 476.64 | 4.38% | 368.831B | +0.94% | +24.48% | Buy
|
|
| 146.33 | 159.76 | 4.29% | 361.021B | +3.83% | +39.02% | Buy
|
|
| 709.18 | 750.92 | 3.11% | 262.217B | +0.71% | +22.39% | Strong Buy
|
|
| 460.73 | 397.32 | 2.96% | 249.085B | +1.97% | +40.76% | Hold
|
|
| 165.61 | 160.19 | 2.44% | 205.349B | +4.03% | +34.93% | Buy
|
|
| 104.57 | 118.52 | 2.16% | 182.141B | +1.88% | -16.54% | Buy
|
|
| 29.95 | 29.26 | 2.03% | 170.705B | +1.70% | +20.28% | Buy
|
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View More| Name
|
Last Price
|
Net Assets
|
Expense Ratio
|
YTD Return
|
|---|---|---|---|---|
| 184.04 | 43.393B | 0.08% | +18.89% | |
| 341.93 | 21.809B | 0.09% | +18.79% | |
| 217.86 | 11.197B | 0.44% | +29.09% | |
| 157.79 | 10.358B | 0.35% | +29.41% | |
| 111.74 | 4.316B | 0.38% | +14.72% |
Mutual Fund Opportunities
View More| Name
|
Last Price
|
Net Assets
|
Expense Ratio
|
YTD Return
|
|---|---|---|---|---|
| 91.87 | 38.313B | 0.27% | +6.52% | |
| 217.83 | 38.313B | 0.27% | +6.48% | |
| 167.33 | 21.809B | 0.09% | +16.25% | |
| 11.44 | 16.876B | 0.00% | +2.94% | |
| 137.99 | 16.876B | 0.00% | +3.58% |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
-
Analyst Report: GSK PLC
GSK plc, based in Brentford, U.K., is a global healthcare company engaged in the discovery, development, manufacture, and marketing of pharmaceutical products. The company's leading products include treatments for asthma and COPD, treatments for HIV infection, and a range of vaccines. The company has active research and development programs in immuno-inflammation, neuroscience, metabolic pathways, ophthalmology, respiratory and infectious diseases, and biopharmaceuticals.
RatingPrice Target -
Analyst Report: Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
RatingPrice Target -
Market Update: CMG, GSK, KO, TROW, NXPI
The major indices are mostly lower at midday. Alphabet disappointed on earnings last night and the stock is being punished -- contributing to the Nasdaq being down more than 1%. But the small-cap Russell 2000 is higher by 1%. Inflation data came in hotter than expected, but GDP for 3Q was stronger than expected. Crude oil is at $100 per barrel. The yield on the 10-year note is at 4.99%.
-
Analyst Report: Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
RatingPrice Target
